166 related articles for article (PubMed ID: 30671946)
1. Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA
Liu XL; Liu JL; Xu YC; Zhang X; Wang YX; Qing LH; Guo W; Ding J; Meng LH
Int J Cancer; 2019 Aug; 145(3):817-829. PubMed ID: 30671946
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
[TBL] [Abstract][Full Text] [Related]
3. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in
Ippen FM; Alvarez-Breckenridge CA; Kuter BM; Fink AL; Bihun IV; Lastrapes M; Penson T; Schmidt SP; Wojtkiewicz GR; Ning J; Subramanian M; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Clin Cancer Res; 2019 Jun; 25(11):3374-3383. PubMed ID: 30796030
[TBL] [Abstract][Full Text] [Related]
4. The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells.
Chakrabarty A; Surendran S; Bhola NE; Mishra VS; Wani TH; Baghel KS; Arteaga CL; Garg R; Chowdhury G
Carcinogenesis; 2019 Oct; 40(10):1179-1190. PubMed ID: 31219154
[TBL] [Abstract][Full Text] [Related]
5. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Cufí S; Corominas-Faja B; Lopez-Bonet E; Bonavia R; Pernas S; López IÁ; Dorca J; Martínez S; López NB; Fernández SD; Cuyàs E; Visa J; Rodríguez-Gallego E; Quirantes-Piné R; Segura-Carretero A; Joven J; Martin-Castillo B; Menendez JA
Oncotarget; 2013 Sep; 4(9):1484-95. PubMed ID: 23986086
[TBL] [Abstract][Full Text] [Related]
6. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
Tateishi K; Nakamura T; Juratli TA; Williams EA; Matsushita Y; Miyake S; Nishi M; Miller JJ; Tummala SS; Fink AL; Lelic N; Koerner MVA; Miyake Y; Sasame J; Fujimoto K; Tanaka T; Minamimoto R; Matsunaga S; Mukaihara S; Shuto T; Taguchi H; Udaka N; Murata H; Ryo A; Yamanaka S; Curry WT; Dias-Santagata D; Yamamoto T; Ichimura K; Batchelor TT; Chi AS; Iafrate AJ; Wakimoto H; Cahill DP
Clin Cancer Res; 2019 Jul; 25(14):4375-4387. PubMed ID: 30975663
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Liu S; Tang Y; Yan M; Jiang W
Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
[TBL] [Abstract][Full Text] [Related]
8. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
Astle MV; Hannan KM; Ng PY; Lee RS; George AJ; Hsu AK; Haupt Y; Hannan RD; Pearson RB
Oncogene; 2012 Apr; 31(15):1949-62. PubMed ID: 21909130
[TBL] [Abstract][Full Text] [Related]
9. Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype.
Madsen RR; Erickson EC; Rueda OM; Robin X; Caldas C; Toker A; Semple RK; Vanhaesebroeck B
PLoS Genet; 2021 Nov; 17(11):e1009876. PubMed ID: 34762647
[TBL] [Abstract][Full Text] [Related]
10. Functional role of SGK3 in PI3K/Pten driven liver tumor development.
Cao H; Xu Z; Wang J; Cigliano A; Pilo MG; Ribback S; Zhang S; Qiao Y; Che L; Pascale RM; Calvisi DF; Chen X
BMC Cancer; 2019 Apr; 19(1):343. PubMed ID: 30975125
[TBL] [Abstract][Full Text] [Related]
11. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
[TBL] [Abstract][Full Text] [Related]
12. Non-tumorigenic epithelial cells secrete MCP-1 and other cytokines that promote cell division in breast cancer cells by activating ERα via PI3K/Akt/mTOR signaling.
Riverso M; Kortenkamp A; Silva E
Int J Biochem Cell Biol; 2014 Aug; 53():281-94. PubMed ID: 24878609
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
[TBL] [Abstract][Full Text] [Related]
14. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Isakoff SJ; Engelman JA; Irie HY; Luo J; Brachmann SM; Pearline RV; Cantley LC; Brugge JS
Cancer Res; 2005 Dec; 65(23):10992-1000. PubMed ID: 16322248
[TBL] [Abstract][Full Text] [Related]
16. LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer.
Henry WS; Hendrickson DG; Beca F; Glass B; Lindahl-Allen M; He L; Ji Z; Struhl K; Beck AH; Rinn JL; Toker A
Oncotarget; 2016 Dec; 7(50):81981-81994. PubMed ID: 27626181
[TBL] [Abstract][Full Text] [Related]
17. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
[TBL] [Abstract][Full Text] [Related]
18. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.
Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE
Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922
[TBL] [Abstract][Full Text] [Related]
19. Human pituitary tumor-transforming gene 1 overexpression reinforces oncogene-induced senescence through CXCR2/p21 signaling in breast cancer cells.
Ruan JW; Liao YC; Lua I; Li MH; Hsu CY; Chen JH
Breast Cancer Res; 2012 Jul; 14(4):R106. PubMed ID: 22789011
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
Citi V; Del Re M; Martelli A; Calderone V; Breschi MC; Danesi R
Cancer Chemother Pharmacol; 2018 Apr; 81(4):745-754. PubMed ID: 29476223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]